1 Thompson CS，Hakim AM. Living beyond our

physiological means：small vessel disease of the brain

is an expression of a systemic failure in arteriolar

function：a unifying hypothesis[J]. Stroke，2009，40：

e322-e330.

2 Pantoni L. Cerebral small vessel disease：from

pathogenesis and clinical characteristics to therapeutic

challenges[J]. Lancet Neurol，2010，9：689-701.

3 Dichgans M. Genetics of ischaemic stroke[J]. Lancet

Neurol，2007，6：149-161.

4 Ballabio E，Bersano A，Bresolin N，et al. Monogenic

vessel diseases related to ischemic stroke：a clinical

approach[J]. J Cereb Blood Flow Metab，2007，27：

1649-1662.

5 Wa rdlaw JM，Smi th EE，Bies sels GJ，e t a l .

Neuroimaging standards for research into small

vessel disease and its contribution to ageing and

neurodegeneration[J]. Lancet Neurol，2013，12：822-

838.

6 Keir SL，Wardlaw JM，Bastin ME，et al. In which

patients is diffusion-weighted magnetic resonance

imaging most useful in routine stroke care?[J]. J

Neuroimaging，2004，14：118-122.

7 Benjamin P，Viessmann O，Mackinnon AD，et al. 7

Tesla MRI in cerebral small vessel disease[J]. Int J

Stroke，2015，10：659-664.

8 Patel B，Markus HS. Magnetic resonance imaging in

cerebral small vessel disease and its use as a surrogate

disease marker[J]. Int J Stroke，2011，6：47-59.

9 van Veluw SJ，Jolink WM，Hendrikse J，et al.

Cortical microinfarcts on 7T MRI in patients with

spontaneous intracerebral hemorrhage[J]. J Cereb

Blood Flow Metab，2014，34：1104-1106.

10 Madai VI，von Samson-Himmelstjerna FC，Bauer M，

et al. Ultrahigh-field MRI in human ischemic stroke

--a 7 tesla study[J]. PLoS One，2012，7：e37631.

11 Theysohn JM，Kraff O，Maderwald S，et al. 7 tesla

MRI of microbleeds and white matter lesions as seen

in vascular dementia[J]. J Magn Reson Imaging，2011，

33：782-791.

12 Sudlow CL，Warlow CP. Comparable studies of the

incidence of stroke and its pathological types：results

from an international collaboration. International

Stroke Incidence Collaboration[J]. Stroke，1997，28：

491-499.

13 O'Sullivan M，Mor r is RG，Markus HS. Br ief

cognitive assessment for patients with cerebral small

vessel disease[J]. J Neurol Neurosurg Psychiatry，

2005，76：1140-1145.

14 Koga H，Takashima Y，Murakawa R，et al. Cognitive

consequences of multiple lacunes and leukoaraiosis as

vascular cognitive impairment in community-dwelling

elderly individuals[J]. J Stroke Cerebrovasc Dis，2009，

18：32-37.

15 Yakushiji Y，Nishiyama M，Yakushiji S，et al. Brain

microbleeds and global cognitive function in adults

without neurological disorder[J]. Stroke，2008，39：

3323-3328.

16 Pantoni L，Poggesi A，Inzitari D. The relation

between white-matter lesions and cognition[J]. Curr

Opin Neurol，2007，20：390-397.

17 LADIS Study Group. 2001-2011：a decade of the

LADIS (Leukoaraiosis And Disability) Study：what

have we learned about white matter changes and

small-vessel disease?[J]. Cerebrovasc Dis，2011，32：

577-588.

18 Jokinen H，Kalska H，Ylikoski R，et al. Longitudinal

cognitive decline in subcortical ischemic vascular

disease--the LADIS Study[J]. Cerebrovasc Dis，2009，

27：384-391.

19 Yamaguchi Y，Wada M，Sato H，et al. Impact of

ambulatory blood pressure variability on cerebral

small vessel disease progression and cognitive decline

in community-based elderly Japanese[J]. Am J

Hypertens，2014，27：1257-1267.

20 Rothwell PM，Howard SC，Dolan E，et al. Effects of

beta blockers and calcium-channel blockers on withinindividual

variability in blood pressure and risk of

stroke[J]. Lancet Neurol，2010，9：469-480.

21 Rothwell PM. Limitations of the usual blood-pressure

hypothesis and importance of variability，instability，

and episodic hypertension[J]. Lancet，2010，375：938-

948.

22 Gorelick PB，Scuteri A，Black SE，et al. Vascular

contributions to cognitive impairment and dementia：

a statement for healthcare professionals from the

Amer ican Heart Association/Amer ican Stroke

Association[J]. Stroke，2011，42：2672-2713.

能下降[29]。

CSVD发病隐匿且临床表现多种多样不易

识别，伴随人口老龄化问题，CSVD导致许多

老年人出现认知、精神和肢体功能障碍，发病

率呈上升趋势，随着医学诊疗水平的不断发展

和人群健康意识的不断提高，早期发现并防治

CSVD意义重大。

中国卒中杂志 2017年２月 第12卷 第２期 151

23 Neumann-Haefelin T，Hoelig S，Berkefeld J，et

al. Leukoaraiosis is a risk factor for symptomatic

intracerebral hemorrhage after thrombolysis for acute

stroke[J]. Stroke，2006，37：2463-2466.

24 Pantoni L，Fierini F，Poggesi A. Thrombolysis in

acute stroke patients with cerebral small vessel

disease[J]. Cerebrovasc Dis，2014，37：5-13.

25 Uchiyama S. Results of the Cilostazol St roke

Prevention Study Ⅱ (CSPS Ⅱ)：a randomized

controlled trial for the comparison of cilostazol and

aspirin in stroke patients[J]. Rinsho Shinkeigaku，

2010，50：832-834.

26 Kav i r ajan H，Sch nei d e r LS. Ef f i c a c y a nd

adverse effects of cholinesterase inhibitors and

memantine in vascular dementia：a meta-analysis

of randomised controlled trials[J]. Lancet Neurol，

2007，6：782-792.

27 Auchus AP，Brashear HR，Salloway S，et a l.

Galantamine treatment of vascular dementia：a

randomized trial[J]. Neurology，2007，69：448-458.

28 Wilcock G，Möbius HJ，Stöffler A. A double-blind，

placebo-controlled multicentre study of memantine

in mild to moderate vascular dementia (MMM500)[J].

Int Clin Psychopharmacol，2002，17：297-305.

29 Pantoni L，del Ser T，Soglian AG，et al. Efficacy and

safety of nimodipine in subcortical vascular dementia：

a randomized placebo-controlled trial[J]. Stroke，

2005，36：619-624.